Drug Type Small molecule drug |
Synonyms 氯苯唑酸葡胺 + [9] |
Target |
Mechanism TTR modulators(Transthyretin modulators) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date EU (16 Nov 2011), |
RegulationOverseas New Drugs Urgently Needed in Clinical Settings (CN), Orphan Drug (JP), Fast Track (US), Breakthrough Therapy (US) |
Molecular FormulaC21H24Cl2N2O8 |
InChIKeyDQJDBUPLRMRBAB-WZTVWXICSA-N |
CAS Registry951395-08-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09674 | Tafamidis Meglumine |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Amyloid Neuropathies | CN | 05 Feb 2020 | |
Cardiomyopathies | US | 03 May 2019 | |
Transthyretin Amyloid Cardiomyopathy | KR | 28 Apr 2015 | |
Amyloid Neuropathies, Familial | JP | 20 Sep 2013 | |
Amyloidosis, Hereditary, Transthyretin-Related | IS | 16 Nov 2011 | |
Amyloidosis, Hereditary, Transthyretin-Related | NO | 16 Nov 2011 | |
Amyloidosis, Hereditary, Transthyretin-Related | LI | 16 Nov 2011 | |
Amyloidosis, Hereditary, Transthyretin-Related | EU | 16 Nov 2011 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Amyloid Neuropathies, Familial | IND Application | ES | 01 Jan 2007 | |
Poikiloderma With Neutropenia | Discovery | BR | 01 Jul 2008 | |
Amyloid Neuropathies, Familial | Discovery | US | 01 Jan 2007 | |
Amyloid Neuropathies, Familial | Discovery | BR | 01 Jan 2007 | |
Amyloid Neuropathies, Familial | Discovery | AR | 01 Jan 2007 | |
Amyloid Neuropathies, Familial | Discovery | GB | 01 Jan 2007 | |
Amyloid Neuropathies, Familial | Discovery | FR | 01 Jan 2007 | |
Amyloid Neuropathies, Familial | Discovery | PT | 01 Jan 2007 | |
Amyloid Neuropathies, Familial | Discovery | SE | 01 Jan 2007 | |
Amyloid Neuropathies, Familial | Discovery | DE | 01 Jan 2007 |
Phase 1 | - | 22 | Tafamidis Free Acid (Tafamidis Free Acid 12.2 mg Oral Tablet (Fasted)) | vasbpvbncf(ttwvwaxjiv) = nxvcvhubsm yksqmemyml (kuzpccrrel, ixfzkxujky - ievyipwhmw) View more | - | 03 Jun 2024 | |
(Tafamidis Meglumine 20 mg Oral Capsule (Fasted)) | vasbpvbncf(ttwvwaxjiv) = yctdysjqxj yksqmemyml (kuzpccrrel, tvprntqdwe - ihjcvmbdyd) View more | ||||||
Phase 4 | 15 | lxjcnoamtd(yqylvfzacx) = kdotnhqkfe cjwovbksyi (zmhtcuovvd, gdgazzldzx - mtyzgzfjye) View more | - | 12 Mar 2024 | |||
Not Applicable | 11 | okthujclie(bylerwkemj) = evmejamlik gmhgnooaqo (mcxqiaphpu ) | - | 25 Aug 2023 | |||
Not Applicable | 1,902 | qqztyobixn(rhrbfvhyuq) = lhlzrplvah cimmxthgvy (ugdhpsbygb ) View more | - | 27 Aug 2021 | |||
Not Applicable | 219 | (przxzzpout) = anovmrmwsg qijwjcixaz (slsajscmqy ) View more | - | 01 Sep 2020 | |||
Not Applicable | - | (asqcuydfpa): hazard ratio = 0.5888 (95% CI, 0.437 - 0.7931), P-Value = 0.0004 | Positive | 28 Aug 2020 | |||
Placebo | |||||||
Not Applicable | Transthyretin Amyloid Cardiomyopathy variant (ATTRm) | wild-type (ATTRwt) TTR | - | (mfrrwfhdiq): hazard ratio = 0.64 (95% CI, 0.47 - 0.85), P-Value = 0.001 | Positive | 01 Sep 2019 | ||
Placebo |